Peter S Hammerman

Peter S Hammerman

UNVERIFIED PROFILE

Are you Peter S Hammerman?   Register this Author

Register author
Peter S Hammerman

Peter S Hammerman

Publications by authors named "Peter S Hammerman"

Are you Peter S Hammerman?   Register this Author

87Publications

3454Reads

15Profile Views

Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.

Oral Dis 2019 Oct 23;25(7):1707-1714. Epub 2019 Jul 23.

Division of Oral Medicine and Dentistry, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/odi.13155DOI Listing
October 2019

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.

Cell Chem Biol 2018 02 21;25(2):135-142.e5. Epub 2017 Dec 21.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389506PMC
February 2018

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Cancer Discov 2016 09 16;6(9):1006-21. Epub 2016 Jun 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010480PMC
September 2016

Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.

Clin Cancer Res 2016 08 29;22(15):3710-2. Epub 2016 Apr 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0582DOI Listing
August 2016

The impact of the MYB-NFIB fusion proto-oncogene in vivo.

Oncotarget 2016 May;7(22):31681-8

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.9426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077968PMC
May 2016

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

J Clin Oncol 2016 Mar 4;34(7):721-30. Epub 2016 Jan 4.

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana-Farber Cancer Institute; Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Pasi A. Jänne, Peter S. Hammerman, and Lynette M. Sholl, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Suman Verma, ResearchDX, Irvine; and James Christensen, Mirati Therapeutics, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.4600DOI Listing
March 2016

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

ACS Chem Biol 2015 Dec 25;10(12):2687-96. Epub 2015 Sep 25.

Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts, United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acschembio.5b00655
Publisher Site
http://dx.doi.org/10.1021/acschembio.5b00655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685943PMC
December 2015

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Cancer Res 2015 Aug 5;75(15):3139-46. Epub 2015 Jun 5.

Lowe Center for Thoracic Oncology, Boston, Massachusetts. Department of Medical Oncology, Boston, Massachusetts. Department of Medicine, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3771DOI Listing
August 2015

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

J Clin Oncol 2015 Jun 27;33(18):1993-4. Epub 2015 Apr 27.

Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.4172DOI Listing
June 2015

Genomic landscape of human papillomavirus-associated cancers.

Clin Cancer Res 2015 May 16;21(9):2009-19. Epub 2015 Mar 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417456PMC
May 2015

Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Clin Cancer Res 2015 May;21(10):2236-43

Department of Medicine (Medical Oncology) and Pathology, University of Colorado Denver, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862209PMC
May 2015

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

Nature 2015 Apr 28;520(7546):239-42. Epub 2015 Jan 28.

1] Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts 02115, USA [2] Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA [3] Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393352PMC
April 2015

Genomic analysis of metastatic cutaneous squamous cell carcinoma.

Clin Cancer Res 2015 Mar 14;21(6):1447-56. Epub 2015 Jan 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359951PMC
March 2015

Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.

Cancer Discov 2015 Mar 2;5(3):239-44. Epub 2015 Feb 2.

Department of Otolaryngology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355279PMC
March 2015

Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.

PLoS One 2015 6;10(2):e0117781. Epub 2015 Feb 6.

Department of Pathology, University of Pittsburgh, Pittsburgh, PA, United States of America; Department of Otolaryngology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117781PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320077PMC
March 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Clin Cancer Res 2014 Dec 7;20(24):6551-8. Epub 2014 Oct 7.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1337DOI Listing
December 2014

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.

Cancer Res 2014 Sep 17;74(17):4676-84. Epub 2014 Jul 17.

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Ludwig Institute for Cancer, Cambridge, Massachusetts. Belfer Institute for Applied Cancer Science, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154986PMC
September 2014

Non-small-cell lung cancers: a heterogeneous set of diseases.

Nat Rev Cancer 2014 Aug;14(8):535-46

1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. [2] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. [3] Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712844PMC
August 2014

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.

Nucleic Acids Res 2014 Jul 26;42(13):e107. Epub 2014 Jun 26.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Department of Internal Medicine, Division of Medical Oncology, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gku489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117748PMC
July 2014

Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.

Cancer Cell 2014 May 1;25(5):590-604. Epub 2014 May 1.

Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Institute For Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.03.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112370PMC
May 2014

Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

J Clin Oncol 2014 Jan 9;32(2):121-8. Epub 2013 Dec 9.

Youngwook Kim, Ji-ae Yoon, Yoomi Lee, Yeong Kyung Yoo, and Keunchil Park, Samsung Medical Center, Samsung Biomedical Research Institute; Jong-Mu Sun, Hong Kwan Kim, Yong Soo Choi, Kwhanmien Kim, Young Mog Shim, Yoon-La Choi, Jhingook Kim, Jin Seok Ahn, Myung-Ju Ahn, and Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine; Sukki Cho, Seoul National University Bundang Hospital, College of Medicine, Seoul National University, Seoul; In-Jae Oh, Kyu-Sik Kim, Sang-Yun Song, Kook-Ju Na, and Young-Chul Kim, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea; Peter S. Hammerman, Jaegil Kim, Chandra Sekhar Pedamallu, Kristian Cibulskis, Michael S. Lawrence, Petar Stojanov, Scott L. Carter, Aaron McKenna, Chip Stewart, Andrey Y. Sivachenko, Gad Getz, and Matthew Meyerson, Broad Institute of Harvard and MIT, Cambridge; Matthew Meyerson, Harvard Medical School; Peter S. Hammerman and Chandra Sekhar Pedamallu, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital Cancer Center, Boston, MA; and Matthew D. Wilkerson and D. Neil Hayes, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.8556DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062710PMC
January 2014

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.

Proc Natl Acad Sci U S A 2014 Jan 6;111(3):1114-9. Epub 2014 Jan 6.

Departments of Otolaryngology, Pharmacology and Chemical Biology, Structural Biology, and Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1319551111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903220PMC
January 2014

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Cancer Discov 2013 Dec 27;3(12):1355-63. Epub 2013 Sep 27.

Departments of 1Medicine and 2Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Ludwig Institute for Cancer Research; 5Department of Neurosurgery, Massachusetts General Hospital; 6Belfer Institute for Applied Cancer Science; 7Department of Pathology, Brigham and Women's Hospital, Boston; 8Broad Institute, Cambridge, Massachusetts; 9UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and 10Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University, Chicago, Illinois; 11Department of Physiology, University of Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864135PMC
December 2013

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

Integrative radiogenomic profiling of squamous cell lung cancer.

Cancer Res 2013 Oct 26;73(20):6289-98. Epub 2013 Aug 26.

Authors' Affiliations: Harvard Radiation Oncology Program; Division of Medical Sciences, Harvard University; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School; Department of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute; Department of Pathology, Brigham and Women's Hospital, Boston; Chemical Biology Program; Howard Hughes Medical Institute, The Broad Institute of MIT and Harvard; Novartis Institute for Biomedical Research; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts; and Department of Medicine, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856255PMC
October 2013

Targeted therapy for squamous cell lung cancer.

Lung Cancer Manag 2012 Dec;1(4):293-300

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA ; Cancer Program, Broad Institute, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt.12.40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744181PMC
December 2012

Cancer gene sequencing: ethical challenges and promises.

Virtual Mentor 2012 Nov 1;14(11):868-72. Epub 2012 Nov 1.

Saint Luke's Hospital, Chesterfield, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/virtualmentor.2012.14.11.stas1-1211DOI Listing
November 2012

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Clin Cancer Res 2009 Dec;15(24):7502-7509

Authors' Affiliations: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0189DOI Listing
December 2009

Fuel feeds function: energy metabolism and the T-cell response.

Nat Rev Immunol 2005 Nov;5(11):844-52

Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nri1710DOI Listing
November 2005

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.

Blood 2005 Jun 10;105(11):4477-83. Epub 2005 Feb 10.

Department of Cancer Biology and Abramson Family Cancer Research Institute, Rm 451 BRB II/III, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-09-3706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895036PMC
June 2005

The Pim kinases control rapamycin-resistant T cell survival and activation.

J Exp Med 2005 Jan 10;201(2):259-66. Epub 2005 Jan 10.

Abramson Family Cancer Research Institute and Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20042020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212793PMC
January 2005

Beginnings of a signal-transduction pathway for bioenergetic control of cell survival.

Trends Biochem Sci 2004 Nov;29(11):586-92

Department of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://www.cell.com/trends/biochemical-sciences/pdf/S0968-00
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S096800040400237
Publisher Site
http://dx.doi.org/10.1016/j.tibs.2004.09.008DOI Listing
November 2004

Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.

Cancer Res 2004 Nov;64(22):8341-8

Department of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6160, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2284DOI Listing
November 2004

Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand.

FASEB J 2004 Aug 4;18(11):1303-5. Epub 2004 Jun 4.

Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.03-1001fjeDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458073PMC
August 2004

Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.

Mol Cell Biol 2003 Oct;23(20):7315-28

Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC230333PMC
http://dx.doi.org/10.1128/mcb.23.20.7315-7328.2003DOI Listing
October 2003

The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.

Genes Dev 2003 Aug 17;17(15):1841-54. Epub 2003 Jul 17.

Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/gad.1105003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC196230PMC
August 2003